Replies to post #563416 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I believe that over time you'll find that most trials for deadly diseases use historical data for comparison and give the experimental drug to all. The PIP is designed that way and I feel certain that new trials for DCVax-Direct will be, as well as any new trials using DCVax-L.

It's very different for therapeutics targeting more minor ailments, but in potentially terminal diseases like most cancers sufficient historical data exists to allow comparison and placebos have very little long term effects. Whether the goal is PFS or OS all should get the experimental therapeutic, hopefully better technics will be found that differentiate between progression and pseudoprogression for PFS based trials.

Gary

[biosectinvestor]

The FDA officials say it in their article that I quoted about ECA’s directly referencing trials like this one. So yes, I am serious. You can suggest otherwise, but those are the facts. The quote I gave, stands for itself. That is the reality. You can choose to believe whatever you want. There is also criticism by actual patients about this trial and not wanting to join if they did not get the experimental treatment because they know the SOC is a guaranteed death sentence for almost all patients. No one likes those odds.